Author’s response to reviews

Title: Ursodeoxycholic acid augmentation in treatment-refractory schizophrenia: A case report

Authors:
Mohsen Khosravi (dr_khosravi2016@yahoo.com)

Version: 1 Date: 22 May 2020

Author’s response to reviews:

Dear Reviewers
I would like to thank you for your valuable comments. The revisions you asked for are listed below:

Note. In order to better understanding the effects of UDCA, Fig. 1 was modified to include only three months (12-week) after the initiation of UDCA.

Reviewer #1
1.Only one reference was used to define TRS.
2. Based on your recommendation, the sentence “Furthermore, there has been no convincing evidence...” was rewritten.
3. Clozapine was eventually terminated due to its adverse effects, including restlessness, tremor, sialorrhea, nausea, and disturbed sleep.
4. Based on your recommendation, ALT levels were included in the text before and after treatment with mirtazapine. ALT level was reported to be 147 U/L after the initiation of mirtazapine, which was mistakenly typed in the text as 47 U/L (the image of the laboratory results has been attached).
5. The statement on the t-test was removed.
6. Based on your recommendation, ALT levels were included in the text before and after treatment with mirtazapine.
7. Figure 2 was removed.
8. Based on your recommendation, the discussion section was rewritten.

Reviewer #2
1. Based on your recommendation, the background section was rewritten, and more focus was placed on this specific therapy (with UDCA).
2. Ethnicity was mentioned.
3. Based on your recommendation, the discussion and conclusions sections were rewritten.
4. Based on your recommendation, the possible mechanisms of the action of UDCA were discussed.